Trial Profile
A prospective pilot trial to study alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- 18 Dec 2015 New trial record